MX2021005992A - Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. - Google Patents
Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.Info
- Publication number
- MX2021005992A MX2021005992A MX2021005992A MX2021005992A MX2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A MX 2021005992 A MX2021005992 A MX 2021005992A
- Authority
- MX
- Mexico
- Prior art keywords
- depression
- gaboxadol
- suicide
- reducing risk
- rapid relief
- Prior art date
Links
- 206010010144 Completed suicide Diseases 0.000 title abstract 2
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 2
- 229950004346 gaboxadol Drugs 0.000 title abstract 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770287P | 2018-11-21 | 2018-11-21 | |
| PCT/US2019/062554 WO2020106927A1 (en) | 2018-11-21 | 2019-11-21 | Gaboxadol for reducing risk of suicide and rapid relief of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005992A true MX2021005992A (es) | 2021-09-14 |
Family
ID=70728606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005992A MX2021005992A (es) | 2018-11-21 | 2019-11-21 | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20220008398A1 (https=) |
| EP (1) | EP3883566A4 (https=) |
| JP (1) | JP2022514194A (https=) |
| KR (1) | KR20210110585A (https=) |
| CN (1) | CN113395962A (https=) |
| AU (1) | AU2019384157A1 (https=) |
| BR (1) | BR112021009944A2 (https=) |
| CA (1) | CA3120856A1 (https=) |
| GB (1) | GB2594616A (https=) |
| IL (1) | IL283311A (https=) |
| MX (1) | MX2021005992A (https=) |
| SG (1) | SG11202105358RA (https=) |
| WO (1) | WO2020106927A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3481387A4 (en) * | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
| US10071083B2 (en) * | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| JP2022514194A (ja) * | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| JP2024020037A (ja) * | 2022-08-01 | 2024-02-14 | 学校法人順天堂 | 痛みと痒みのバイオマーカー |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| CL2004001603A1 (es) | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| TW200509918A (en) | 2003-06-25 | 2005-03-16 | Lundbeck & Co As H | Treatment of depression and other affective disorders |
| TW200501951A (en) | 2003-06-25 | 2005-01-16 | Lundbeck & Co As H | Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis |
| BRPI0410857A (pt) | 2003-06-25 | 2006-07-04 | Lundbeck & Co As H | método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica |
| US20050234093A1 (en) | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
| US20050137222A1 (en) | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| JP2007530604A (ja) | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
| ZA200607427B (en) | 2004-04-02 | 2009-02-25 | Lundbeck & Co As H | Treatment of impaired respiratory function with gaboxadol |
| GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPH SHAPES OF A GABAA AGONIST |
| US20080262029A1 (en) | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
| DE102005020882A1 (de) | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20080159958A1 (en) | 2006-12-27 | 2008-07-03 | Abbott Laboratories | Determination of histamine-3 bioactivity |
| TW200920358A (en) | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090048288A1 (en) | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| GB0810063D0 (en) | 2008-06-03 | 2008-07-09 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| EP2334299A1 (en) | 2008-09-01 | 2011-06-22 | H. Lundbeck A/S | Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat |
| US11083732B2 (en) | 2014-03-31 | 2021-08-10 | University Of Maryland, Baltimore | Use of negative modulators of GABA receptors containing alpha5 subunits as fast acting antidepressants |
| WO2015171547A1 (en) | 2014-05-05 | 2015-11-12 | Ovid Therapeutics Inc. | Methods of treating cognitive impairment associated with neurodegenerative disorders |
| RS62007B1 (sr) | 2014-06-06 | 2021-07-30 | Ovid Therapeutics Inc | Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma |
| US20170304358A1 (en) | 2014-10-06 | 2017-10-26 | Seyyed Nassir GHAEMI | Primary and secondary prevention of dementias and suicide with trace dose lithium |
| LT3274331T (lt) | 2015-03-24 | 2020-04-10 | H. Lundbeck A/S | 4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-olio gamybos būdas |
| WO2016176609A1 (en) | 2015-04-30 | 2016-11-03 | Ovid Therapeutics Inc | Methods of treating prader-willi syndrome |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| AR105378A1 (es) | 2015-07-17 | 2017-09-27 | Ovid Therapeutics Inc | Métodos de tratamiento de trastornos del desarrollo con gaboxadol |
| EP4541420A3 (en) | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| AR105670A1 (es) | 2015-08-11 | 2017-10-25 | Ovid Therapeutics Inc | Métodos de sedación parenteral para usar durante el tratamiento de cuidados intensivos |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| JP6857647B2 (ja) | 2015-08-11 | 2021-04-14 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤 |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| US20170119704A1 (en) | 2015-10-13 | 2017-05-04 | Ovid Therapeutics Inc. | Treatment of cognitive impairment |
| WO2017205606A1 (en) | 2016-05-26 | 2017-11-30 | Ovid Therapeutics Inc. | Methods of treating behavioral syndromes using pipradrol |
| EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
| CN110225754A (zh) | 2016-11-22 | 2019-09-10 | 奥维德医疗公司 | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 |
| US10737984B2 (en) | 2016-11-30 | 2020-08-11 | Hrl Laboratories, Llc | Formulations and methods for 3D printing of ceramic matrix composites |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| CN110621318A (zh) | 2017-03-15 | 2019-12-27 | 奥维德医疗公司 | 排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途 |
| US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| WO2018222957A1 (en) | 2017-06-01 | 2018-12-06 | Ovid Therapeutics Inc. | Treatment of developmental disorders with imidazolone derivatives |
| WO2019006161A1 (en) | 2017-06-28 | 2019-01-03 | Ovid Therapeutics Inc. | TREATMENT OF DEVELOPMENT SYNDROMES |
| JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
| AU2018320849A1 (en) | 2017-08-25 | 2020-03-05 | Ovid Therapeutics Inc. | Recombinant adeno-associated vectors |
| JP2020533415A (ja) | 2017-09-12 | 2020-11-19 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ナルコレプシーの処置におけるガボキサドールの使用 |
| CN107595850A (zh) | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种有效提高睡眠质量的药物组合物及其用途 |
| JP2021521103A (ja) | 2018-04-06 | 2021-08-26 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 物質使用障害の処置におけるガボキサドールの使用 |
| JP2022514194A (ja) * | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
-
2019
- 2019-11-21 JP JP2021529111A patent/JP2022514194A/ja active Pending
- 2019-11-21 US US17/295,845 patent/US20220008398A1/en not_active Abandoned
- 2019-11-21 CN CN201980089656.6A patent/CN113395962A/zh active Pending
- 2019-11-21 SG SG11202105358RA patent/SG11202105358RA/en unknown
- 2019-11-21 BR BR112021009944-1A patent/BR112021009944A2/pt not_active IP Right Cessation
- 2019-11-21 AU AU2019384157A patent/AU2019384157A1/en not_active Abandoned
- 2019-11-21 US US16/691,049 patent/US11123332B2/en not_active Expired - Fee Related
- 2019-11-21 KR KR1020217019089A patent/KR20210110585A/ko not_active Ceased
- 2019-11-21 CA CA3120856A patent/CA3120856A1/en active Pending
- 2019-11-21 MX MX2021005992A patent/MX2021005992A/es unknown
- 2019-11-21 EP EP19886329.2A patent/EP3883566A4/en not_active Withdrawn
- 2019-11-21 WO PCT/US2019/062554 patent/WO2020106927A1/en not_active Ceased
- 2019-11-21 GB GB2108720.0A patent/GB2594616A/en not_active Withdrawn
-
2021
- 2021-04-02 US US17/221,178 patent/US20220054461A1/en not_active Abandoned
- 2021-05-20 IL IL283311A patent/IL283311A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB202108720D0 (en) | 2021-08-04 |
| US20200155522A1 (en) | 2020-05-21 |
| JP2022514194A (ja) | 2022-02-10 |
| KR20210110585A (ko) | 2021-09-08 |
| US20220054461A1 (en) | 2022-02-24 |
| AU2019384157A1 (en) | 2021-06-17 |
| US20220008398A1 (en) | 2022-01-13 |
| CA3120856A1 (en) | 2020-05-28 |
| CN113395962A (zh) | 2021-09-14 |
| EP3883566A1 (en) | 2021-09-29 |
| BR112021009944A2 (pt) | 2021-08-17 |
| GB2594616A (en) | 2021-11-03 |
| WO2020106927A1 (en) | 2020-05-28 |
| SG11202105358RA (en) | 2021-06-29 |
| IL283311A (en) | 2021-07-29 |
| US11123332B2 (en) | 2021-09-21 |
| EP3883566A4 (en) | 2022-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005992A (es) | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. | |
| MX2021002321A (es) | Nuevos metodos. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| MX2020009773A (es) | Terapia de combinacion. | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| EP4335418A3 (en) | Compositions and methods for treating pterygium | |
| EP4378524A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
| MX2009008582A (es) | Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| WO2019157056A8 (en) | Treatment of patients with classic fabry disease | |
| PH12020551726A1 (en) | Treatment of atopic dermatitis | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| MX2020001727A (es) | Terapia de combinacion. | |
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| MX2023015097A (es) | Tratamiento de sintomas asociados a neoplasias mieloproliferativas. | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| NZ797744A (en) | Intradialytic use of sodium nitrite | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME |